Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report released on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.

Aptevo Therapeutics Price Performance

APVO opened at $0.39 on Friday. The business has a 50 day simple moving average of $0.44 and a 200-day simple moving average of $2.25. Aptevo Therapeutics has a 12 month low of $0.28 and a 12 month high of $21.64.

Aptevo Therapeutics (NASDAQ:APVO) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, topping the consensus estimate of ($1.93) by $0.26. On average, equities research analysts predict that Aptevo Therapeutics will post -8.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is owned by institutional investors and hedge funds.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.